Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy.
Blood Cell Ther
; 6(4): 129-134, 2023 Nov 25.
Article
in En
| MEDLINE
| ID: mdl-38149020
ABSTRACT
Introduction:
Cytokine release syndrome (CRS) is a life-threatening side effect of chimeric antigen receptor T (CAR-T) cell therapy. This study investigated whether serum inorganic phosphate (IP) and magnesium (Mg) levels are predictive markers of CRS development.Methods:
This single-center retrospective cohort study enrolled 16 consecutive patients with diffuse large B-cell lymphoma who had received CAR-T cell therapy. Logistic regression models with generalized estimating equations were used to evaluate whether changes in IP and Mg levels from their baseline values were associated with the development of CRS within 48 hours.Results:
Decreased IP and Mg levels from baseline (per 10% change) were associated with an increased CRS incidence (adjusted odds ratio 2.18 [95% confidence interval (CI), 1.31-3.62], 3.18 [95% CI, 1.57-6.44], respectively).Conclusions:
Changes in IP and Mg concentrations within 48 hours may be useful predictive markers of CRS onset.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Blood Cell Ther
Year:
2023
Document type:
Article
Affiliation country:
Japón
Country of publication:
Japón